Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
3
×
life sciences
national blog main
national top stories
blueprint medicines
cancer
clinical trials
drugs
indiana blog main
indiana top stories
new york blog main
new york top stories
roche
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
akcea therapeutics
anylam pharmaceuticals
avapritinib
biotech
boston
boulder/denver blog main
boulder/denver top stories
cancer drugs
capmatinib
cardiomyopathy
companion diagnostic
detroit blog main
detroit top stories
dna sequencing
eli lilly
entrectinib
europe blog main
europe top stories
express scripts
fda
foundation medicine
gastrointestinal stromal tumors
What
drug
fda
3
×
genetic
3
×
approved
cancer
medicines
oks
address
ago
akcea
alnylam
amyloidosis
approval
approves
attr
available
battle
blueprint
carries
certain
debilitating
deeper
designed
disease
dna
fingerprint
going
latest
matter
medicine
nd
new
pass
patients
pfizer
rare
ret
second
sets
signature
Language
unset
Current search:
genetic
×
fda
×
" boston top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues